This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.
Mainstream media has begun to illustrate just how effective medical marijuana can be in helping cancer patients. The American Cancer Society reported that studies have consistently shown that during clinicaltrials patients who used marijuana extracts needed less pain medicine and opioids.
Florida medical marijuana doctors are recommending medical marijuana for anxiety, depression and many other mental health conditions. Anxiety is one aspect of a broader condition- anxiety disorder. Even mainstream media has delved into the medicinal properties of cannabis and the science-based culture that cannabis heals.
Despite the novelty of its drug policy findings, the document has gone largely unnoticed by reform advocates and the media. The panel, led by Jake Leinenkugel (a presidential nominee), asserted that psychedelics, such as MDMA and psilocybin, as well as cannabis, present promising ways to treat mental health conditions among military veterans.
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com.
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. US Food and Drug Administration website. Accessed October 17, 2022.
Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinicaltrials.
Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.
Media Contact: Will Johnson. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.
Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Marijuana Preferred Over Pain Pills. A broad-based study conducted by Florida International University looked at information from the National Survey on Drug Use and Health.
SPL026 entered clinicaltrials at the beginning of 2021 and this designation marks an important step forward towards an accelerated drug approval pathway for bringing the benefits of SPL026 to market for patients suffering with MDD.”. Small Pharma initiated a clinical program into DMT-assisted therapy in February 2021.
Media: media@mymd.com. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.
Which begs the question: Why is it okay for Big Pharma to profit from high-potency THC drugs, while Florida patients can’t use high-potency THC medical marijuana to treat documented health conditions under a physician’s care? Instead of restricting free speech, the FTC recommends parents practice “media literacy.”. How to learn more.
What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? This is because these types of studies control the most variables to ensure that the results that come out of the trial are as reliable as possible. The cannabis research problem.
Dementia is a catch-all term for the conditions that cause declining memory and thinking skills, including Alzheimer’s, Parkinson’s and vascular dementia. In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. Cannabis research in the U.S.
While many health conditions can be treated with more traditional pharmaceuticals, plant-based products may be a safer and healthier option – or at least a safe health supplement. By interacting with the receptors of the ECS, cannabis modulates the bodily functions that cause or exacerbate health conditions.
Scott will work closely with the management team to further develop the company’s internal and external communications with a focus on strategy, branding, social media presence and investor communications. Anebulo Pharmaceuticals, Inc. Scott Anderson. Head of Investor Relations and Public Relations. 858) 229-7063. scott@anebulo.com.
The Victorian and New South Wales Governments had both begun clinicaltrials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.
At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Supera-CBD is currently on a path toward human clinicaltrials as a therapy for epilepsy, followed by chronic pain.
From the pressures of work and personal relationships to the constant bombardment of information on social media and the news, many individuals find themselves struggling to cope with these challenges. The prevalence of anxiety disorders and stress-related conditions has risen significantly in recent decades.
Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. All investor and media enquiries. media enquiries. media enquiries. What about other medical cannabis products? “The
Curaleaf CURLF, -7.27% is “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” the FDA wrote. Mental conditions like anxiety, depression, and PTSD.”.
At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.
The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.
Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders. Media Portrayal and Its Role in Shaping Medical Cannabis Attitudes Media plays a pivotal role in shaping public perception, and the portrayal of medical cannabis is no exception.
However, we firmly disagree that the referenced clinicaltrials are in fact “substantial,” as the trials were extremely limited in scope, and funding and the publication of these trials were limited. 9] While that portion of the statement provoked a few breathless media reports, it was old news.
The opening of London’s first such clinic follows the opening of Britain’s first medical cannabis clinic in Greater Manchester earlier in the year. Access is clearly in demand from Londoners as there is already a waiting list of 150 patients at the London clinic ahead of its opening.
Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinicaltrials before they can conclude certain products as GRAS. “To
ELE-Psilo program expected to enter clinicaltrials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.
The doctor diagnoses the condition and chooses a specific medicine. That there’s not enough information about, there’s not enough clinicaltrials, and there’s not enough this and that. They get pumped out through the media and everybody’s talking about how dangerous it is.
This was notoriously reflected in the 2020 arrest of a Japanese man and woman for speaking positively about using cannabis in social media posts. Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. The future of weed legalization in Japan.
Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Conclusions. Background.
Depression can be situational, but Clinical Depression, which comes and goes and/or lasts for more than a few days, is a chemical imbalance within the central nervous system. Depression can make these conditions worse and vice versa. The NIMH states that women are often more affected by Depression than men.
Sunshine Coast based Tikun Oceana, formerly known as Medifarm , is now under the control of administrators from Cor Cordis.The company was founded …… Predictably Murdoch media has this behind a paywall if you want to pay to learn more. Different strains for different conditions. Media event date: 27 August 2019.
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinicaltrials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT . 831-429-6362 ext 303.
. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. Media Contact. In addition, Gb Sciences has 12 U.S. 31, 2021.
“As MMJ International Holdings continues to advance to its clinicaltrials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.
There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinicaltrials are needed. Media Contact : John Kanakis. The Neo Exchange Inc.
Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.
Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Delic is focused on bringing psychedelic wellness to the mainstream.
The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.
o Technology powered research: Virtual clinicaltrials and other accelerated technologies that mix the potential of new technologies with cannabis to create research insights quickly and more accurately, are being classified as Cannabis 3.0, triggering new innovations and improved data quality through better user experiences.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content